Delving into the Latest Updates on Avidin Ltd. with Synapse

概览

疾病领域	数量

肿瘤	2
神经系统疾病	2
血液及淋巴系统疾病	1
免疫系统疾病	1

排名前五的药物类型	数量

化学药	6
小分子化药	2

关联

12

项与 Avidin Ltd. 相关的药物

Q-134R

靶点-

作用机制-

在研机构

Avidin Ltd.

原研机构

Avidin Ltd.

在研适应症

阿尔茨海默症

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

QAM-2203

靶点-

作用机制-

在研机构

Avidin Ltd.

原研机构

Avidin Ltd.

在研适应症

神经系统疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

AVE-021

靶点-

作用机制-

在研机构

Avidin Ltd.

原研机构

Avidin Ltd.

在研适应症

银屑病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Avidin Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Avidin Ltd. 相关的专利（医药）

登录后查看更多信息

61

项与 Avidin Ltd. 相关的文献（医药）

2023-07-18·Vaccines

Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model.

Article

作者: Szebeni, Gábor J ; Balog, József Á ; Tiszlavicz, László ; Nagy, Lajos I ; Neuperger, Patrícia ; Alföldi, Róbert ; Gémes, Nikolett ; Puskás, László G

The advent of immunotherapy has revolutionized cancer treatments. However, the application of immune checkpoint inhibitors may entail severe side effects, with the risk of therapeutic resistance. The generation of chimeric antigen receptor (CAR) T-cells or CAR-NK cells requires specialized molecular laboratories, is costly, and is difficult to adapt to the rapidly growing number of cancer patients. To provide a simpler but effective immune therapy, a whole-cell tumor vaccine protocol was established based on ultraviolet C (UCV)-irradiated 4T1 triple-negative breast cancer cells. The apoptosis of tumor cells after UVC irradiation was verified using resazurin and Annexin V/propidium iodide flow cytometric assays. Protective immunity was achieved in immunized BALB/c mice, showing partial remission. Adoptive transfer of splenocytes or plasma from the mice in remission showed a protective effect in the naive BALB/c mice that received a living 4T1 tumor cell injection. 4T1-specific IgG antibodies were recorded in the plasma of the mice following immunization with the whole-cell vaccine. Interleukin-2 (IL-2) and oligonucleotide 2006 (ODN2006) adjuvants were used for the transfer of splenocytes from C57BL/6 mice into cyclophosphamide-treated BALB/c mice, resulting in prolonged survival, reduced tumor growth, and remission in 33% of the cases, without the development of the graft-versus-host disease. Our approach offers a simple, cost-effective whole-cell vaccine protocol that can be administered to immunocompetent healthy organisms. The plasma or the adoptive transfer of HLA-matching immunized donor-derived leukocytes could be used as an immune cell therapy for cancer patients.

2023-01-01·Frontiers in medicine

Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.

Article

作者: Szebeni, Gabor J ; Rónaszéki, Benedek ; Nagy, Lajos I ; Farkas, Katalin ; Balog, Attila ; Szabó, Enikő ; Neuperger, Patrícia ; Hackler, László ; Balog, József Á ; Modok, Szabolcs ; Gémes, Nikolett ; Faragó, Anna ; Puskás, László G

BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these patients is limited with the comparison of mRNA-based, vector-based or inactivated virus-based vaccines.MethodsForty-nine HD patients and 46 healthy controls (HCs) were enrolled who received two-doses complete vaccination with BNT162b2, or AZD1222, or BBIBP-CorV, respectively. The antibodies reactive to the receptor binding domain of spike protein of SARS-CoV-2 were assayed by Siemens ADVIA Centaur assay. The reactive cellular immunity was assayed by flow cytometry. The PBMCs were reactivated with SARS-CoV-2 antigens and the production of activation-induced markers (TNF-α, IFN-γ, CD40L) was measured in CD4⁺ or CD8⁺ T-cells ex vivo.ResultsThe anti-RBD IgG level was the highest upon BNT162b2 vaccination in HDs (1264 BAU/mL) vs. HCs (1325 BAU/mL) among the studied groups. The BBIBP-CorV vaccination in HDs (339.8 BAU/mL ^***p < 0.001) and AZD1222 in HDs (669.9 BAU/mL *p < 0.05) resulted in weaker antibody response vs. BNT162b2 in HCs. The response rate of IgG production of HC vs. HD patients above the diagnostic cut-off value was 100% vs. 72% for the mRNA-based BNT162b2 vaccine; 93% vs. 56% for the vector-based AZD1222, or 69% vs. 33% for the inactivated vaccine BBIBP-CorV, respectively. Cases that underwent the anti-CD20 therapy resulted in significantly weaker (^**p < 0.01) anti-RBD IgG level (302 BAU/mL) than without CD20 blocking in the HD group (928 BAU/mL). The response rates of CD4⁺ TNF-α⁺, CD4⁺ IFN-γ⁺, or CD4⁺ CD40L⁺ cases were lower in HDs vs. HCs in all vaccine groups. However, the BBIBP-CorV vaccine resulted the highest CD4⁺ TNF-α and CD4⁺ IFN-γ⁺ T-cell mediated immunity in the HD group.ConclusionWe have demonstrated a significant weaker overall response to vaccines in the immunologically impaired HD population vs. HCs regardless of vaccine type. Although, the humoral immune activity against SARS-CoV-2 can be highly evoked by mRNA-based BNT162b2 vaccination compared to vector-based AZD1222 vaccine, or inactivated virus vaccine BBIBP-CorV, whereas the CD4⁺ T-cell mediated cellular activity was highest in HDs vaccinated with BBIBP-CorV.

2022-11-01·Cancer Control4区 · 医学

Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients

4区 · 医学

ArticleOA

作者: Puskás, László G. ; Gyöngyi, Zoltán ; Kovács, Beáta Zs. ; Somlyai, Ildikó ; Fórizs, István ; Nagy, Lajos I. ; Czuppon, György ; Papp, András ; Somlyai, Gábor

The possible role of the naturally occurring deuterium in the regulation of cell division was first described in the 1990s. To investigate the mechanism of influence of deuterium (D) on cell growth, expression of 236 cancer-related and 536 kinase genes were tested in deuterium-depleted (40 and 80 ppm) and deuterium-enriched (300 ppm) media compared to natural D level (150 ppm). Among genes with expression changes exceeding 30% and copy numbers over 30 (124 and 135 genes, respectively) 97.3% of them was upregulated at 300 ppm D-concentration. In mice exposed to chemical carcinogen, one-year survival data showed that deuterium-depleted water (DDW) with 30 ppm D as drinking water prevented tumor development. One quarter of the treated male mice survived 344 days, the females 334 days, while one quarter of the control mice survived only 188 and 156 days, respectively. In our human retrospective study 204 previously treated cancer patients with disease in remission, who consumed DDW, were followed. Cumulative follow-up time was 1024 years, and average follow-up time per patient, 5 years (median: 3.6 years). One hundred and fifty-six patients out of 204 (77.9%) did not relapse during their 803 years cumulative follow-up time. Median survival time (MST) was not calculable due to the extremely low death rate (11 cancer-related deaths, 5.4% of the study population). Importantly, 8 out of 11 deaths occurred several years after stopping DDW consumption, confirming that regular consumption of DDW can prevent recurrence of cancer. These findings point to the likely mechanism in which consumption of DDW keeps D-concentration below natural levels, preventing the D/H ratio from increasing to the threshold required for cell division. This in turn can serve as a key to reduce the relapse rate of cancer patients and/or to reduce cancer incidence in healthy populations.

100 项与 Avidin Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Avidin Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月21日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

7

1

临床1期

其他

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Q-134R	阿尔茨海默症更多	临床1期
AVM-92	结肠癌更多	临床前
Prostiazol	结肠炎更多	临床前
ACF516	囊性纤维化更多	临床前
C-142	结肠炎更多	临床前